secwatch.observer — SEC 8-K summary
======================================

Issuer:     PURE BIOSCIENCE, INC. (PURE)
CIK:        0001006028
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001493152-24-007825
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Pure Bioscience shareholders approve increase in authorized shares to 200M
--------------------------------------------------------------------------

- All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.
- Ratification of Weinberg & Company as auditor for FY ending July 31, 2024 approved (99.58%).
- Non-binding advisory vote on executive compensation passed with 99.14% of votes cast.
- 2024 Equity Incentive Plan adopted with 99.17% of votes cast.
- Amendment to increase authorized common stock from 150M to 200M shares approved with 55.13% of outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/0001493152-24-007825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006028/000149315224007825/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer